8 / 16
Page 41
allied
academies
Case Reports in Surgery and Invasive Procedures | Volume 3
March 11-12, 2019 | London, UK
Biomarkers
Plastic and Cosmetic Surgery
International Conference on
International Conference on
Joint Event
&
Notes:
Elevated levels of anti-tumor immunity related markers and cells are the best correlates of long-term
survival in SCLC
Farhad Kosari
Mayo Clinic, USA
Introduction
: While most small cell lung cancer (SCLC) patients
die within a few months, a sub-group of patients survive
for many years. Factors determining long-term survivorship
remain largely unknown. We present the first comprehensive
comparative genomic and tumor microenvironment analyses of
small cell lung cancer (SCLC) between patients with long term
(LTS) and expected (EXS) survival times.
Methods
: We compared surgically resected tumors of 23 LTS
(survival>4 years) and 18 EXS (survival≤2 years). There were
no differences in clinical variables including TNM staging and
curative versus non-curative intend surgery between the groups.
Gene expression profiling was performed by microarrays and
tumor microenvironment analyses were by IHC of prominent
immune related markers.
Results
: Immune related genes and pathways represented
the majority of the differentially overexpressed genes in LTS
compared to the EXS. The differences in the immunological
tumor-microenvironment were confirmed by quantitative
immuno-staining. Increased numbers of tumor infiltrating and
associated lymphocytes were present throughout tumors of
LTS. Several differentiating patterns of enhanced anti-tumor
immunity were identified. While some areas of LTS tumors
also harbored higher numbers of suppressive immune cells
(monocytes, regulatory lymphocytes, and macrophages), ratios
of these suppressive cells to CD3+ lymphocytes were generally
lower in LTS tumors indicating a more tumor suppressive
microenvironment.
Conclusions
: Our data demonstrate that long-term survivorship
of SCLC patients is strongly influenced by the presence of
anti-tumor immune cells in the tumor microenvironment.
Characterization of the anti-tumor immune responses may
identify opportunities for individualized immunotherapies for
SCLC.
e:
kosari.farhad@mayo.edu